Inflammation and Therapy for Hypertension

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2010 Jun 5

PMID 20524088

Citations 4

Authors

Cheryl L Laffer

Fernando Elijovich

Affiliations

Soon will be listed here.

Abstract

It is currently accepted that hypertension, atherosclerosis, and diabetes are disorders with subtle or overt activation of inflammatory mediators. Therefore, it has become increasingly important to ascertain whether current antihypertensive drug families have proinflammatory or anti-inflammatory actions that modify the outcomes of their hemodynamic effects on blood pressure. We review the current state of knowledge about the effects of the major classes of available antihypertensive agents on inflammation and speculate on the possible contribution of these effects to observations in clinical trials. We suggest that a strategy of drug development specifically addressing inflammation in hypertension may provide increased benefit in terms of target organ damage, and we describe some examples of these promising developments.

Citing Articles

Evidence that angiotensin II does not directly stimulate the MD2-TLR4 innate inflammatory pathway.

Okechukwu C, Pirro N, Chappell M Peptides. 2020; 136:170436.

PMID: 33181267 PMC: 7855779. DOI: 10.1016/j.peptides.2020.170436.

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.

Silva I, Figueiredo R, Rios D Int J Mol Sci. 2019; 20(14).

PMID: 31337127 PMC: 6678872. DOI: 10.3390/ijms20143458.

Inhibitor κB kinase 2 is a myosin light chain kinase in vascular smooth muscle.

Ying Z, do Carmo J, Xiang L, da Silva A, Chen M, Ryan M Circ Res. 2013; 113(5):562-70.

PMID: 23817200 PMC: 3970202. DOI: 10.1161/CIRCRESAHA.113.301510.

Diversity through phosphine catalysis identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven immunity.

Cruz D, Wang Z, Kibbie J, Modlin R, Kwon O Proc Natl Acad Sci U S A. 2011; 108(17):6769-74.

PMID: 21383121 PMC: 3084088. DOI: 10.1073/pnas.1015254108.

References

Luther J, Gainer J, Murphey L, Yu C, Vaughan D, Morrow J . Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006; 48(6):1050-7. DOI: 10.1161/01.HYP.0000248135.97380.76. View

Bakris G, Sarafidis P, Weir M, Dahlof B, Pitt B, Jamerson K . Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375(9721):1173-81. DOI: 10.1016/S0140-6736(09)62100-0. View

Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H . Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens. 2008; 22(2):145-50. DOI: 10.1038/ajh.2008.344. View

On Y, Kim C, Sohn D, Oh B, Lee M, Park Y . Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. Korean J Intern Med. 2002; 17(2):131-7. PMC: 4531666. DOI: 10.3904/kjim.2002.17.2.131. View

Weber M, Black H, Bakris G, Krum H, Linas S, Weiss R . A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9699):1423-31. DOI: 10.1016/S0140-6736(09)61500-2. View

Li J, Li Q, Xie X, Ao Y, Tie C, Song R . Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats. Eur J Pharmacol. 2009; 620(1-3):97-104. DOI: 10.1016/j.ejphar.2009.08.021. View

Lorenzo O, Ruiz-Ortega M, Suzuki Y, Ruperez M, Esteban V, Sugaya T . Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol. 2002; 13(5):1162-1171. DOI: 10.1681/ASN.V1351162. View

Schram M, van Ittersum F, Spoelstra-de Man A, van Dijk R, Schalkwijk C, IJzerman R . Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind,.... J Hum Hypertens. 2005; 19(6):429-37. DOI: 10.1038/sj.jhh.1001812. View

Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H . Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006; 47(4):656-64. DOI: 10.1161/01.HYP.0000203772.78696.67. View

10.

Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S . Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 2009; 385(2):269-72. DOI: 10.1016/j.bbrc.2009.05.061. View

11.

Boesen E, Sasser J, Saleh M, Potter W, Woods M, Warner T . Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. Am J Physiol Renal Physiol. 2008; 295(2):F446-53. PMC: 2519182. DOI: 10.1152/ajprenal.00095.2008. View

12.

Syngle A, Vohra K, Kaur L, Sharma S . Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand J Rheumatol. 2008; 38(1):15-22. DOI: 10.1080/03009740802279709. View

13.

Martin-Ventura J, Munoz-Garcia B, Blanco-Colio L, Martin-Conejero A, Madrigal-Matute J, Vega M . Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl. 2008; (111):S71-4. DOI: 10.1038/ki.2008.521. View

14.

Rossig L, Haendeler J, Mallat Z, Hugel B, Freyssinet J, Tedgui A . Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000; 36(7):2081-9. DOI: 10.1016/s0735-1097(00)01002-0. View

15.

Singh V, Le B, Khode R, Baker K, Kumar R . Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297-306. PMC: 2584136. DOI: 10.2337/db08-0805. View

16.

Schmidt A, Flick B, Jahn E, Bramlage P . Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers. Vasc Health Risk Manag. 2008; 4(4):909-15. PMC: 2597762. View

17.

Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

18.

Rahman S, Lauten W, Khan Q, Navalkar S, Parthasarathy S, Khan B . Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol. 2002; 89(6):686-90. DOI: 10.1016/s0002-9149(01)02340-2. View

19.

Westendorp B, Hamming I, Szymanski M, Navis G, Goor H, Buikema H . Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor. Eur J Pharmacol. 2008; 602(2-3):373-9. DOI: 10.1016/j.ejphar.2008.11.055. View

20.

Matsubara M, Akizuki O, Ikeda J, Saeki K, Yao K, Sasaki K . Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats. Eur J Pharmacol. 2007; 580(1-2):201-13. DOI: 10.1016/j.ejphar.2007.10.072. View